Key takeaways:

Aficamten improved peak oxygen uptake at 24 weeks vs. metoprolol in patients with obstructive hypertrophic cardiomyopathy.

Aficamten appeared to be as safe as metoprolol in this population.

Perspective from Dipti Itchhaporia, MD, MACC, FESC, FAHA

In patients with obstructive hypertrophic cardiomyopathy, the cardiac myosin inhibitor aficamten was superior to the beta-blocker metoprolol for improving symptoms and peak oxygen uptake, according to results of the MAPLE-HCM trial.

For MAPLE-HCM, presented at the European Society of Cardiology Congress and simultaneously published in The New England Journal of Medicine , the researchers randomly assigned 175 patients with obstructive HCM (mean age, 58 years; 58.3% men) to receive aficamten (Cytokinetics) 5 mg to 20 mg o

See Full Page